FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551112729> ?p ?o ?g. }

• W1551112729 endingPage "1147" @default.
• W1551112729 startingPage "1147" @default.
• W1551112729 abstract "4884 Recent studies have suggested that tumors might escape from host immunity through PD-L/PD-1 interaction. We have recently reported that PD-L expression in human esophageal cancer is an independent prognostic factor (Clin Cancer Res. 2005,11:2947). In the following study, we have also found that PD-L1 expression has similar prognostic value in pancreatic cancer. These clinical data suggest that PD-L/PD-1 pathway may play a pivotal role in human cancer including these aggressive and intractable cancers. In this study, we have examined therapeutic efficacy of targeting T cell negative pathway toward clinical application. To this end, we utilized murine syngeneic tumor models. In hepatic metastasis model, a murine colon cancer, CT26 was inoculated into the spleen in syngeneic BALB/c mice. We treated mice with anti-PD-1 (RMP1-14), anti-PD-L1 (MIH-5), anti-PD-L2 (TY25) mAb or control Ig starting on the day of tumor inoculation. Hepatic metastasis has been significantly inhibited by either anti-PD-1 or PD-L2, but not PD-L1 mAb compared to controls at 3 weeks after inoculation (the median number of metastases; anti-PD-1, 5, anti-PD-L1, 25, anti-PD-L2, 7, control Ig, 27). The in vivo experiments of CD4 or CD8 T cell depletion revealed that the inhibition of tumor metastasis by PD-1 blockade was mainly mediated by CD8 T cell subset. Interestingly, the coadministration of anti-CTLA-4 mAb (4F10) with PD-1 blockade further enhanced antitumor immunity and resulted in complete inhibition of liver metastasis, although CTLA-4 blockade alone was less effective and insufficient for complete inhibition. Thus, the combination of PD-1 and CTLA-4 blockade displayed synergistic effects on the inhibition of tumor metastasis. Then, we applied this combined blockade therapy of PD-1 and CTLA-4 to the advanced tumor. CT26 was subcutaneously inoculated in the flank of mice. When tumor reached 6-8 mm in diameter around 10 days after inoculation, the treatment of both anti-PD-1 and anti-CTLA-4 mAbs was started. Compared to mice treated with control Ig, the simultaneous blockade of PD-1 and CTLA-4 induced substantial antitumor effect in vivo. Tumors were either completely rejected or significantly inhibited in all mice by 2 weeks after treatment. By histology, much more cell recruitments and necrosis in the established tumor were observed during mAb treatment compared to control. Immunohistochemical analysis revealed that the treatment promoted the infiltrations of tumor-reactive T cells, predominantly CD8 T cell, into the tumor. There was no overt toxicity in mice during and after the treatment. In conclusion, we have demonstrated for the first time that simultaneous blockade of differential T cell negative regulatory pathways of PD-L/PD-1 and B7/CTLA-4 evoked powerful tumor immunity in vivo. Thus, we suggest that this promising strategy is potentially effective in treatment of tumor metastasis and advanced tumors in humans." @default.
• W1551112729 created "2016-06-24" @default.
• W1551112729 creator A5018521703 @default.
• W1551112729 creator A5029231452 @default.
• W1551112729 creator A5035027513 @default.
• W1551112729 creator A5044881516 @default.
• W1551112729 creator A5063129930 @default.
• W1551112729 creator A5066136586 @default.
• W1551112729 creator A5066319891 @default.
• W1551112729 creator A5070494006 @default.
• W1551112729 creator A5073275097 @default.
• W1551112729 creator A5073463502 @default.
• W1551112729 creator A5087155470 @default.
• W1551112729 date "2006-04-15" @default.
• W1551112729 modified "2023-09-22" @default.
• W1551112729 title "Significant therapeutic efficacy of blocking T cell negative regulatory pathway in vivo" @default.
• W1551112729 hasPublicationYear "2006" @default.
• W1551112729 type Work @default.
• W1551112729 sameAs 1551112729 @default.
• W1551112729 citedByCount "0" @default.
• W1551112729 crossrefType "journal-article" @default.
• W1551112729 hasAuthorship W1551112729A5018521703 @default.
• W1551112729 hasAuthorship W1551112729A5029231452 @default.
• W1551112729 hasAuthorship W1551112729A5035027513 @default.
• W1551112729 hasAuthorship W1551112729A5044881516 @default.
• W1551112729 hasAuthorship W1551112729A5063129930 @default.
• W1551112729 hasAuthorship W1551112729A5066136586 @default.
• W1551112729 hasAuthorship W1551112729A5066319891 @default.
• W1551112729 hasAuthorship W1551112729A5070494006 @default.
• W1551112729 hasAuthorship W1551112729A5073275097 @default.
• W1551112729 hasAuthorship W1551112729A5073463502 @default.
• W1551112729 hasAuthorship W1551112729A5087155470 @default.
• W1551112729 hasConcept C121608353 @default.
• W1551112729 hasConcept C126322002 @default.
• W1551112729 hasConcept C150903083 @default.
• W1551112729 hasConcept C159654299 @default.
• W1551112729 hasConcept C167672396 @default.
• W1551112729 hasConcept C170493617 @default.
• W1551112729 hasConcept C203014093 @default.
• W1551112729 hasConcept C207001950 @default.
• W1551112729 hasConcept C2776090121 @default.
• W1551112729 hasConcept C2777701055 @default.
• W1551112729 hasConcept C2778468042 @default.
• W1551112729 hasConcept C2779013556 @default.
• W1551112729 hasConcept C2780931953 @default.
• W1551112729 hasConcept C2781053074 @default.
• W1551112729 hasConcept C45121317 @default.
• W1551112729 hasConcept C502942594 @default.
• W1551112729 hasConcept C71924100 @default.
• W1551112729 hasConcept C86803240 @default.
• W1551112729 hasConcept C8891405 @default.
• W1551112729 hasConceptScore W1551112729C121608353 @default.
• W1551112729 hasConceptScore W1551112729C126322002 @default.
• W1551112729 hasConceptScore W1551112729C150903083 @default.
• W1551112729 hasConceptScore W1551112729C159654299 @default.
• W1551112729 hasConceptScore W1551112729C167672396 @default.
• W1551112729 hasConceptScore W1551112729C170493617 @default.
• W1551112729 hasConceptScore W1551112729C203014093 @default.
• W1551112729 hasConceptScore W1551112729C207001950 @default.
• W1551112729 hasConceptScore W1551112729C2776090121 @default.
• W1551112729 hasConceptScore W1551112729C2777701055 @default.
• W1551112729 hasConceptScore W1551112729C2778468042 @default.
• W1551112729 hasConceptScore W1551112729C2779013556 @default.
• W1551112729 hasConceptScore W1551112729C2780931953 @default.
• W1551112729 hasConceptScore W1551112729C2781053074 @default.
• W1551112729 hasConceptScore W1551112729C45121317 @default.
• W1551112729 hasConceptScore W1551112729C502942594 @default.
• W1551112729 hasConceptScore W1551112729C71924100 @default.
• W1551112729 hasConceptScore W1551112729C86803240 @default.
• W1551112729 hasConceptScore W1551112729C8891405 @default.
• W1551112729 hasOpenAccess W1551112729 @default.
• W1551112729 hasRelatedWork W1160892457 @default.
• W1551112729 hasRelatedWork W1437729609 @default.
• W1551112729 hasRelatedWork W1495788311 @default.
• W1551112729 hasRelatedWork W1496502278 @default.
• W1551112729 hasRelatedWork W2395000660 @default.
• W1551112729 hasRelatedWork W2408012595 @default.
• W1551112729 hasRelatedWork W2476999556 @default.
• W1551112729 hasRelatedWork W2502634075 @default.
• W1551112729 hasRelatedWork W2541860579 @default.
• W1551112729 hasRelatedWork W2754718069 @default.
• W1551112729 hasRelatedWork W2800516248 @default.
• W1551112729 hasRelatedWork W2931391344 @default.
• W1551112729 hasRelatedWork W2940611353 @default.
• W1551112729 hasRelatedWork W2952471974 @default.
• W1551112729 hasRelatedWork W2952893925 @default.
• W1551112729 hasRelatedWork W2954574035 @default.
• W1551112729 hasRelatedWork W2982372328 @default.
• W1551112729 hasRelatedWork W2996080149 @default.
• W1551112729 hasRelatedWork W3083110487 @default.
• W1551112729 hasRelatedWork W3213762896 @default.
• W1551112729 hasVolume "66" @default.
• W1551112729 isParatext "false" @default.
• W1551112729 isRetracted "false" @default.
• W1551112729 magId "1551112729" @default.
• W1551112729 workType "article" @default.